Study S000226

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 456906 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03175211
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: COMPLETED
Enrollment: 20
Start: 2017-06-30
Primary completion: 2018-02-19
Lead sponsor: Boehringer Ingelheim
Conditions: Healthy
Interventions: DRUG:BI 456906; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2017-000295-29; NIH:2017

Registered primary outcomes

[N (%)] of subjects with drug-related adverse events. [Up to 672 hours]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007419	Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Jungnik A, Diabetes, obesity & metabolism	2023	Other trial	PMID 36527386 DOI	cites ClinicalTrials.gov:NCT03175211; registry reference DERIVED:36527386